Ribociclib Lowers Risk of Disease Recurrence by 25% for Early Breast Cancer

Ribociclib (Kisqali) demonstrated a 26% risk reduction in distant disease-free survival and a 28% risk reduction in recurrence-free survival in patients with HR+/HER2- early breast cancer.

Related Keywords

United States ,American ,Shreeram Aradhye ,Dennisj Slamon ,Ribociclib Kisqali ,Translational Research In Oncology ,American Society Of Clinical Oncology Annual Meeting ,Clinical Translational Research ,Novartis ,Global Drug Development ,Clinical Oncology Annual ,Translational Research ,California Los Angeles ,Jonsson Comprehensive Cancer Center ,